- Home
- ACLX vs VRNS Comparison
ACLX vs VRNS Comparison
Compare ACLX & VRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$114.46
HOLD
Current Price
$24.30
Company Overview
Basic Information| Metric | ACLX | VRNS |
|---|---|---|
| Founded | 2015 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.0B |
| IPO Year | 2022 | 2013 |
Fundamental Metrics
Financial Performance| Metric | ACLX | VRNS |
|---|---|---|
| Price | $114.46 | $24.30 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 15 | 21 |
| Target Price | ★ $115.85 | $45.62 |
| AVG Volume (30 Days) | ★ 3.5M | 3.2M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | $22,286,000.00 | ★ $270,288,000.00 |
| Revenue This Year | $329.40 | $18.88 |
| Revenue Next Year | $151.37 | $17.59 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 24.35 |
| 52 Week Low | $47.86 | $20.06 |
| 52 Week High | $114.65 | $63.90 |
Technical Indicators
Market Signals| Indicator | ACLX | VRNS |
|---|---|---|
| Relative Strength Index (RSI) | 83.82 | 43.41 |
| Support Level | $64.61 | $20.34 |
| Resistance Level | N/A | $28.26 |
| Average True Range (ATR) | 1.13 | 1.44 |
| MACD | 2.30 | 0.40 |
| Stochastic Oscillator | 99.34 | 67.09 |
Price Performance
Historical Comparison ACLX
VRNS
About ACLX Arcellx Inc.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.
About VRNS Varonis Systems Inc.
Varonis Systems is a cybersecurity vendor focused on data privacy and security. The firm is currently undergoing a cloud transition as it weans its on-premises customers over to its cloud products that are delivered as software-as-a-service. The New York-based firm was founded in 2005 and went public in 2014.